CLNN
Clene Inc (CLNN)
Consumer Defensive • NASDAQ • $7.28-1.49%
- Symbol
- CLNN
- Exchange
- NASDAQ
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Price
- $7.28
- Daily Change
- -1.49%
- Market Cap
- $85.75M
- Trailing P/E
- N/A
- Forward P/E
- -3.73
- 52W High
- $13.50
- 52W Low
- $2.28
- Analyst Target
- $30.67
- Dividend Yield
- N/A
- Beta
- 0.89
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clin…
Company websiteResearch CLNN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.